Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Leyre Bento, Fernando Martín Moro, Antonio Gutierrez, Ana Jiménez Ubieto, Alberto López, Blanca Sánchez González, Belén Navarro, Alicia Segura, Mireia Franch, Ana García-Noblejas, Eva Donato, Alejandro Martín García-Sancho, Beatriz De La Cruz, Alfonso Ortiz Algarra, Roberto Trelles-Martínez, Javier López, Carlos Grande, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2024-203615

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Maria Gomes Da Silva, Gilles Crochet, Jarosław Dybko, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Maeve O'Reilly, Bertram Glass, Ana Maria Sureda Balari, Peter Dreger, Olivier Hermine, Ali Bazarbachi

Blood (2024) 144 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2024-205389

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Blood (2024) 144 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2024-199742

Published: 2024

Journal Articles

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Almudena Cabero Martínez, Ana García Bacelar, Begoña Mendibil Esquisabel, Javier Nuñez Cespedes, Ana Jiménez Ubieto, Eukene Gainza Gonzalez, Elena Perez Ceballos, Beatriz De La Cruz, Ana Garcia Noblejas, Paula Fernández-Caldas, Norma C. Gutierrez, Blanca Sánchez-González, Rocío Figueroa Mora, Alberto Lopez Garcia, Daniel García Belmonte, Maria Sanchez de Castro, Estefania Cerezo Velasco, Xabier Martin Martitegui, Hugo Daniel Luzardo Henríquez, Jordina Rovira, Luis Antonio Lopez Gomez, Jackeline Solano, Ana Torres Tienza, Maria Stefania Infante, Raquel Santiago Alonso, Raquel Del Campo, Dunia De Miguel Llorente, Alicia Roldán-Pérez, Emilia Pardal, Beatriz Gonzalez Mena, Miguel Ángel Rodríguez Gil, Nazaret Domínguez Velasco, Albert Blanco Juan, Maria Alejandra Blum Dominguez, Javier López Marin, María Peñarrubia-Ponce, Mariana Bastos-Oreiro, Alejandro Martín García-Sancho

Blood (2024) 144 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2024-198904

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Alexander P. Boardman, Juan Luis Reguera, Paul Spin, Pearl Wang, Lamees Almuallem, Jenna Ellis, Jamie Zheng, Jinender Kumar, Thalia Farazi, Alejandro Martín García-Sancho, Koji Izutsu

Blood (2024) 144 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2024-197948

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2023-174242

Published: 2023

Journal Articles

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Santiago Montes-Moreno, Sr., Aitana Avendaño, Sonia Gonzalez De Villambrosia, Laura Rodriguez-Merino, Jordi Morata, Raul Tonda, Estrella Carrillo-Cruz, Carlos Grande, Jose Maria Roncero, Jaime Perez De Oteyza, Concepcion Nicolas, Beatriz Rey Búa, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez, Alejandro Martin Garcia-Sancho, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2023-179150

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Cecilia Carpio, Manjusha Namuduri, Nazia Iqbal, Dishan Liu, Nickolas Sophos, Min Zhu, Ayesha Sabir, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Alejandro Martín García-Sancho

Blood (2023) 142 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2023-179964

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

NARROW

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only